Free Trial

ProPhase Labs (PRPH) Competitors

ProPhase Labs logo
$0.51 -0.02 (-3.82%)
Closing price 04:00 PM Eastern
Extended Trading
$0.52 +0.01 (+2.00%)
As of 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PRPH vs. CLNN, VTVT, KLRS, IMMX, IZTC, ASRT, EQ, UNCY, VXRT, and XBIT

Should you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Clene (CLNN), vTv Therapeutics (VTVT), Kalaris Therapeutics (KLRS), Immix Biopharma (IMMX), Invizyne Technologies (IZTC), Assertio (ASRT), Equillium (EQ), Unicycive Therapeutics (UNCY), Vaxart (VXRT), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry.

ProPhase Labs vs. Its Competitors

Clene (NASDAQ:CLNN) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Clene presently has a consensus target price of $32.60, suggesting a potential upside of 278.19%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts plainly believe Clene is more favorable than ProPhase Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clene
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
ProPhase Labs
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

23.3% of Clene shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 35.3% of Clene shares are owned by insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Clene has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.62, indicating that its share price is 162% less volatile than the S&P 500.

Clene has higher earnings, but lower revenue than ProPhase Labs. Clene is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clene$340K255.30-$39.40M-$3.76-2.29
ProPhase Labs$5.59M3.78-$53.36M-$1.26-0.40

ProPhase Labs has a net margin of 0.00% compared to Clene's net margin of -10,386.36%. Clene's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Clene-10,386.36% N/A -125.49%
ProPhase Labs N/A -262.42%-76.48%

In the previous week, Clene had 5 more articles in the media than ProPhase Labs. MarketBeat recorded 6 mentions for Clene and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 1.53 beat Clene's score of 0.62 indicating that ProPhase Labs is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Clene
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ProPhase Labs
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Clene beats ProPhase Labs on 10 of the 16 factors compared between the two stocks.

Get ProPhase Labs News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRPH vs. The Competition

MetricProPhase LabsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$21.14M$2.65B$6.12B$10.62B
Dividend YieldN/A57.79%5.72%4.85%
P/E Ratio-0.4023.6229.2227.30
Price / Sales3.78587.23492.28183.90
Price / CashN/A27.2425.8230.35
Price / Book2.045.4112.476.65
Net Income-$53.36M$33.06M$3.32B$276.14M
7 Day Performance-3.20%1.37%1.86%0.01%
1 Month Performance31.27%10.18%8.39%3.60%
1 Year Performance-78.80%-2.10%63.48%32.72%

ProPhase Labs Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRPH
ProPhase Labs
0.7063 of 5 stars
$0.51
-3.8%
N/A-78.0%$21.14M$5.59M-0.40130Positive News
Gap Down
CLNN
Clene
3.8945 of 5 stars
$8.25
-4.1%
$32.60
+295.2%
+46.8%$86.55M$340K-2.19100News Coverage
VTVT
vTv Therapeutics
1.4203 of 5 stars
$21.81
-0.2%
$35.50
+62.8%
+48.1%$86.10M$1.02M-6.999
KLRS
Kalaris Therapeutics
1.4277 of 5 stars
$4.76
+7.0%
$3.00
-37.0%
N/A$83.23MN/A0.00110
IMMX
Immix Biopharma
3.2528 of 5 stars
$2.50
flat
$8.00
+220.0%
+78.5%$82.59MN/A-3.259
IZTC
Invizyne Technologies
N/A$12.95
-4.1%
N/AN/A$80.96MN/A0.0029Gap Up
ASRT
Assertio
2.8706 of 5 stars
$0.84
+0.9%
$2.38
+182.0%
-28.5%$80.36M$124.96M-1.8720Positive News
EQ
Equillium
0.4729 of 5 stars
$1.28
-4.5%
$1.00
-21.9%
+29.2%$79.73M$41.10M-2.2940Short Interest ↑
UNCY
Unicycive Therapeutics
2.676 of 5 stars
$4.49
+1.1%
$57.00
+1,169.5%
+16.6%$78.42M$680K-1.099
VXRT
Vaxart
1.7696 of 5 stars
$0.34
-2.4%
$2.00
+489.6%
-56.7%$77.66M$47.40M-1.26120News Coverage
XBIT
XBiotech
2.1133 of 5 stars
$2.56
+0.8%
N/A-67.2%$77.44M$4.01M-2.78100News Coverage
Short Interest ↓

Related Companies and Tools


This page (NASDAQ:PRPH) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners